Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Biohaven Pharmaceutical Holding Company Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Biohaven Pharmaceutical Holding Company Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 30 Nov 2022 | Lorem |
| ALS drug trial readouts to watch in 2022 | 10 Jan 2022 | William Newton |
| AbbVie’s atogepant, Biohaven’s Nurtec ODT for preventive migraine may not cause approved mAbs as many headaches as market expects, experts say | 23 Apr 2021 | William Newton |
| Biohaven’s zavegepant has potential positive impact in Phase II COVID-19 study though broad MOA, limited understanding of immune system's role raises some expert concern | 07 Oct 2020 | William Newton |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer